ANFH1 is associated with the COL2A1 gene, located on chromosome 12. The condition follows an autosomal dominant inheritance pattern, meaning a pathogenic variant in one copy of the gene is associated with the condition. No ClinVar variant data is certified in this packet, so the spectrum of reported variants cannot be described here. According to expert review, no clinically meaningful genotype-phenotype correlations for COL2A1 have been identified, in part because the number of reported individuals remains relatively small. Penetrance is reported as 100%, meaning individuals who carry a relevant pathogenic variant are expected to show features of the condition.

No formal diagnostic criteria for this condition have been established, according to expert review. Diagnostic methods are not certified in this packet beyond what GeneReviews describes for the related condition spondylometaphyseal dysplasia, corner fracture type, which shares the COL2A1 gene association. Per that expert review, diagnosis is typically suspected based on clinical and radiographic features alongside family history. No newborn screening program for this condition is indicated in this packet. Molecular testing for COL2A1 variants may be relevant in the context of clinical evaluation, though no specific testing hierarchy is certified here.

No foundational or FDA-approved therapies are certified in this packet for ANFH1. Recombinant human platelet-derived growth factor BB holds an orphan drug designation for this condition; this designation is distinct from FDA approval and does not indicate the agent is currently approved or available as a treatment. According to expert review of a related COL2A1-associated condition, supportive care aimed at improving quality of life and reducing complications is practiced, often involving multidisciplinary input. For individuals with joint pain, activities that place significant strain on joints are generally avoided in favor of joint-friendly alternatives such as swimming or cycling, per that same expert review.

Natural history and prognosis data specific to ANFH1 are not certified in this packet. Expert review of a related condition associated with COL2A1 notes that affected individuals may experience complications including coxa vara, scoliosis, and chronic pain, though this clinical description pertains to a broader COL2A1-related skeletal dysplasia syndrome rather than specifically to ANFH1. No further course, survival, or outcome information is available from certified sources in this packet, and no additional prognosis claims can be made on that basis.

Several certified active trial records are present for conditions related to avascular necrosis and hip disease. These include a study assessing autologous bone marrow aspirate treatment for early-stage osteonecrosis (NCT06123481, sponsored by Johns Hopkins University) and studies evaluating total hip arthroplasty devices, including the SYMBOL range (NCT05227924, Dedienne Sante S.A.S.), the Z1 Hip System (NCT07104279, Zimmer Biomet), the Medacta SMS system (NCT02748408, Medacta International SA), and EMPHASYS Cup positioning with navigation technology (NCT06631638, DePuy Orthopaedics). Active clinical trials for this condition are listed on ClinicalTrials.gov.